deoxycytidine has been researched along with Malignant Melanoma in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (17.02) | 18.7374 |
| 1990's | 3 (6.38) | 18.2507 |
| 2000's | 23 (48.94) | 29.6817 |
| 2010's | 11 (23.40) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Garri, DD; Karamysheva, АF; Moiseeva, NI; Saakyan, SV; Tsygankov, АY | 1 |
| Curiel, TJ; Deng, Y; Gupta, HB; Kancharla, A; Kari, S; Kornepati, AVR; Li, R; Osta, E; Padron, AS; Reyes, RM; Sun, X; Svatek, RS; Vadlamudi, R; Wu, B; Zhang, D | 1 |
| Bonazzi, V; Daignault, SM; Fernando, M; Gabrielli, B; Haass, NK; Lanagan, C; Larsen, JE; Nazareth, D; Oo, ZY; Proctor, M; Škalamera, D; Snell, C; Stevenson, AJ; Walpole, S | 1 |
| Fan, X; Ge, S; Jia, R; Song, X; Wang, J; Xu, X; Zhang, H; Zhang, Y; Zhou, Y | 1 |
| Cooper, A; Grey, A; Grimison, P; McNeil, C; O'Toole, S; Thompson, J | 1 |
| Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP | 1 |
| Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A | 1 |
| Ishii, M; Kikuta, J; Naito, Y; Ogawa, K; Otani, K; Sakaguchi, Y; Seo, Y; Takahashi, Y | 1 |
| Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K | 3 |
| Black, JM; Boh, EE; Farris, PK; Hodari, KT; Lewis, AT; Rogers, N | 1 |
| Cui, Z; Lansakara-P, DS; Li, X; Zhu, S | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Bogenrieder, T; Landthaler, M; Schölmerich, J; Stolz, W; Weitzel, C | 1 |
| Clippe, C; Ligneau, B; Trillet-Lenoir, V | 1 |
| Corrie, PG; Cree, IA; Haass, N; Hengge, U; Kuwert, C; Neuber, K; Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Zutt, M | 1 |
| Bui, DT; Fruehauf, JP; Holcombe, RF; Kong, KM; Sommers, KR | 1 |
| Eskerski, H; Haberkorn, U; Kleinschmidt, J; Mier, W; Paschen, A; Rothfels, H; Schadendorf, D; Schoensiegel, F; Sieger, S | 1 |
| Becker, JC; Bröcker, EB; Terheyden, P | 1 |
| Bechrakis, N; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, J; Thiel, E | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Bergman, AM; Breistøl, K; Comijn, EM; Fodstad, O; Hendriks, HR; Kuiper, CM; Myhren, F; Noordhuis, P; Peters, GJ; Sandvold, ML; Smid, K; Voorn, DA | 1 |
| Benimetskaya, L; Hua, E; Khvorova, A; Lai, JC; Miller, P; Stein, CA; Wu, S; Zhang, LM | 1 |
| Cree, IA; Kurbacher, CM; Neale, MH; Reinhold, U | 1 |
| Bulusu, R; Corrie, PG; Cree, IA; Hartley, JA; Jonson, A; Mayer, A; Sehmbi, R; Shaw, J; Spanswick, VJ | 1 |
| Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E | 1 |
| Blanco-Aparicio, C; Carnero, A; Fominaya, J; Leal, JF; Moneo, V; Pequeño, B; Romero, L; Velasco, J | 1 |
| Bechrakis, NE; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
| Benimetskaya, L; Miller, P; Stein, CA | 1 |
| Bechrakis, NE; Foerster, MH; Keilholz, U; Martus, P; Schmidt-Hieber, M; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
| Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| Hayward, IP; Parsons, PG | 1 |
| Aamdal, S; Eppelbaum, R; Franklin, H; Sessa, C; Smyth, JF; Sulkes, A; Ten Bokkel Huinink, W; Vermorken, J; Wanders, J; Wolff, I | 1 |
| Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN | 1 |
| Endo, Y; Matsuda, A; Obata, T; Sasaki, T; Tanaka, M; Uchida, H | 1 |
| Davidson, RL; Reff, ME | 1 |
| Bobo, B; Drewinko, B | 1 |
| Davidson, RL; Horn, D | 1 |
| Arita, M; Fujii, A; Matsuda, A; Okumoto, T; Sakata, S; Sasaki, T; Ueda, T; Yamagami, K | 1 |
| Greig, R; Kline, T; Mallon, F; Poste, G; Trainer, DL | 1 |
| Davis, MA; Lawrence, TS | 1 |
| Lönn, S; Lönn, U; Nylen, U; Winblad, G | 1 |
| Ashman, CR; Davidson, RL; Kaufman, ER | 1 |
2 review(s) available for deoxycytidine and Malignant Melanoma
| Article | Year |
|---|---|
[Role of gemcitabine in the treatment of other malignant tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
Bromodeoxyuridine mutagenesis and deoxyribonucleotide pool imbalance in mammalian cells.
Topics: Animals; Base Composition; Bromodeoxyuridine; Cell Line; Cricetinae; Cytarabine; Deoxyadenosines; Deoxycytidine; Deoxyguanosine; Deoxyribonucleotides; DNA; Drug Resistance; Fluorouracil; Hydroxyurea; Melanoma; Mutation; Ribonucleotide Reductases; Sister Chromatid Exchange; Thymidine | 1985 |
14 trial(s) available for deoxycytidine and Malignant Melanoma
| Article | Year |
|---|---|
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors | 2015 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pilot Projects; Survival Analysis; Uveal Neoplasms | 2003 |
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome; Uveal Neoplasms | 2004 |
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Treatment Outcome; Uveal Neoplasms | 2004 |
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Uveal Neoplasms | 2005 |
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leukopenia; Male; Melanoma; Middle Aged; Survival Analysis; Thrombocytopenia; Uveal Neoplasms | 2005 |
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Uveal Neoplasms | 2005 |
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Uveal Neoplasms | 2006 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance | 2007 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Recurrence; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neutropenia; Stomach Neoplasms | 1994 |
31 other study(ies) available for deoxycytidine and Malignant Melanoma
| Article | Year |
|---|---|
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; Choroid Neoplasms; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Phenylacetates; Primary Cell Culture; Retinyl Esters; Tumor Cells, Cultured; Uveal Neoplasms; Valproic Acid | 2020 |
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Autophagy; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; Urinary Bladder Neoplasms | 2021 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors | 2019 |
The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Uveal Neoplasms | 2014 |
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease Progression; Fatal Outcome; Fluorouracil; Genes, ras; Humans; Indoles; Male; Melanoma; Mutation; Neoplasms, Second Primary; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
Cell-cycle-controlled radiation therapy was effective for treating a murine malignant melanoma cell line in vitro and in vivo.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Gemcitabine; Humans; Melanocytes; Melanoma; Mice; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Exudative, nonhealing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Eruptions; Fluorouracil; Humans; Male; Melanoma; Scalp Dermatoses; Severity of Illness Index; Skin Neoplasms | 2011 |
Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Lysosomes; Melanoma; Mice; Mice, Inbred C57BL; Micelles; Polyethylene Glycols; Prodrugs; Stearic Acids | 2012 |
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Fluorouracil; Humans; Hutchinson's Melanotic Freckle; Male; Melanoma; Middle Aged; Neoplasms, Second Primary; Nevus, Pigmented; Prodrugs; Skin; Skin Neoplasms | 2002 |
Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Radiography; Skin Neoplasms; Stevens-Johnson Syndrome | 2003 |
MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
Topics: Animals; Antiviral Agents; Bromodeoxycytidine; Cell Line, Tumor; Cell Separation; Cloning, Molecular; Deoxycytidine; Dependovirus; Enhancer Elements, Genetic; Extracellular Matrix Proteins; Female; Flow Cytometry; Ganciclovir; Gene Transfer Techniques; Genes, Reporter; Genetic Therapy; Humans; Immunosuppressive Agents; Melanoma; Mice; Mice, Nude; Models, Genetic; Monophenol Monooxygenase; Neoplasm Proteins; Neoplasm Transplantation; Plasmids; Promoter Regions, Genetic; Proteins; Simplexvirus; Thymidine Kinase; Time Factors; Tissue Distribution | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; DNA; DNA Damage; Fatty Acids; Gemcitabine; Humans; Inhibitory Concentration 50; Leukemia; Melanoma; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Nucleoside Deaminases; Phosphorylation; Rats; Time Factors | 2004 |
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured | 2004 |
Treosulfan and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Humans; Melanoma; Reproducibility of Results; Uveal Neoplasms | 2005 |
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
Topics: bcl-2-Associated X Protein; bcl-X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Deoxycytidine; DNA-Binding Proteins; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Genes, Tumor Suppressor; Humans; Inhibitory Concentration 50; Leiomyosarcoma; Melanoma; Mitochondria; Morpholines; Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides | 2005 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Uveal Neoplasms | 2008 |
Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells.
Topics: Alkylating Agents; Antineoplastic Agents; Cell Line; Dacarbazine; Deoxycytidine; Deoxyguanosine; Genes; Humans; Melanoma; Theophylline; Thymidine | 1984 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay | 1999 |
Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Fibrosarcoma; Gene Deletion; Gene Expression; Humans; Inhibitory Concentration 50; Melanoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Deoxycytidine reverses the suppression of pigmentation caused by 5-BrdUrd without changing the distribution of 5-BrdUrd in DNA.
Topics: Animals; Bromodeoxyuridine; Cell Line; Cricetinae; Deoxycytidine; DNA Replication; DNA, Neoplasm; Kinetics; Melanoma; Monophenol Monooxygenase; Nucleic Acid Renaturation; Pigments, Biological | 1979 |
Inhibition of [3H]TdR and [3H]CdR incorporation in an established human lymphoma cell line by trypsin treatment.
Topics: Animals; Cell Line; Cell Separation; Deoxycytidine; DNA, Neoplasm; HeLa Cells; Humans; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Experimental; Sarcoma, Experimental; Thymidine; Trypsin | 1978 |
Inhibition of biological effects of bromodeoxyuridine by deoxycytidine: correlation with decreased incorporation of bromodeoxyuridine into DNA.
Topics: Animals; Bromodeoxyuridine; Cell Line; Contact Inhibition; Cricetinae; Culture Media; Deoxycytidine; DNA, Neoplasm; In Vitro Techniques; Melanoma; Neoplasm Transplantation; Neoplasms, Experimental; Pigmentation | 1976 |
Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
Topics: Animals; Cytarabine; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Leukemia P388; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms; Tumor Cells, Cultured | 1991 |
Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells.
Topics: Animals; Azacitidine; Deoxycytidine; DNA, Neoplasm; Female; Lung Neoplasms; Melanoma; Methylation; Mice; Mice, Inbred C57BL; Neoplasm Metastasis | 1985 |
Selective radiosensitization and cytotoxicity of human melanoma cells using halogenated deoxycytidines and tetrahydrouridine.
Topics: Antineoplastic Agents; Bromodeoxycytidine; Cell Line; Deoxycytidine; Fibroblasts; Humans; In Vitro Techniques; Melanoma; Radiation-Sensitizing Agents; Tetrahydrouridine; Tumor Cells, Cultured; Uridine | 1989 |
Reduced DNA damage induced in human melanoma cells by dacarbazine in the presence of deoxyribonucleosides.
Topics: Dacarbazine; Deoxyadenosines; Deoxycytidine; Deoxyguanosine; DNA Damage; DNA, Neoplasm; Humans; Melanoma; Thymidine | 1989 |